Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Encrypgen Continues To Make Inroads Despite The Altcoin Market's Struggles

|About: Encrypgen USD (DNA-USD), Includes: BTC-USD

Encrypgen (DNA) continues to successfully build the business.

The company has several upcoming catalysts which will prove to be impactful.

Utility may come sooner than expected.

In 2017, there was incredible enthusiasm for altcoins.  At times, they even experienced harder pumps than Bitcoin.  But, several years later, while Bitcoin appears to still have a ton of momentum, altcoins appear to be dead for the most part.  The fact is that most projects haven’t materialized the way their supporters were hoping for.  Going forward, it’s certainly possible that 90% of altcoins won’t recover and that only the ones with industry changing potential will prosper.  Crypto traders interested in finding the next gems should take focus their attention on utility tokens, rather than security tokens.  The success of utility tokens will depend entirely on the ability of their management teams to build a successful business, rather than hyping up the native currency.  One company with a utility token that continues to make solid progress is Encrypgen (DNA).

One of the major reasons why Encrypgen appears to be so promising is that its platform, the Gene-Chain, could make a huge contribution to the field of genomics.  For anyone who doesn’t know, genomics is going to play a major role in the future in providing clues about why certain diseases act the way they do, and what can be done to stop them.  Of course, in order for researchers to get that far, they need access to genomic data.  Encrypgen is utilizing blockchain technology in a way that will make accessing that data easier than ever before.  Zion Market Research estimates that the global genomics market will reach$41.2 billion by the year 2025.  If Encrypgen can score just a small piece of that, the business should prosper.

Upcoming Catalysts

In the world of cryptocurrency, there have been many projects which failed to live up to expectations.  Fortunately, Encrypgen isn’t one of them.  The company has routinely delivered on all of their plans.  The rest of 2019 is sure to be an exciting time and token holders can look forward to the following developments:

HODL Rewards Program Series A Capital Raise First Active Study Engagement Research Consortium B2B Product Launch in September

All five of these catalysts will continue moving the business forward and on track for success.  The HODL rewards program is expected to launch within shortly and will incentivize data sellers to keep their DNA tokens on the Gene-Chain.  In doing so, they will earn additional DNA tokens based on their wallet balance.  It’s a great way to not only incentivize current data sellers but also encourage new data sellers to join the Encrypgen community and start making some additional money.  It’s a fantastic way to generate passive income.

Additionally, the company is working on a Series A capital raise that will provide funding to ramp up marketing.  And it won’t be for crypto marketing which has zero impact on the business.  Instead, the company will be able to generate precision marketing that targets data sellers and buyers.  As I said earlier, success will be based on the company’s ability to generate utility, not crypto hype.

The Gene-Chain has already had quite a few data transactions take place and it is likely that many more will occur shortly thanks to Encrypgen’s first active study.  This study will involve a common ailment and it is likely that data buyers will be purchasing quite a few data samples in the coming months.  So, for those who haven’t yet uploaded their data, now is the time to do so.

Concluding Thoughts

Encrypgen is building its business the right way by focusing on generating utility.  Utility is the name of the game here and based on the upcoming catalysts, utility may be coming a lot sooner than previously expected. Onward and upward.

Disclosure: I am/we are long DNA-USD.